Collecting Blood and Tissue Samples for HIV-Related Cancer Research
Collects blood and tissue samples from adults with HIV and related cancers for research.
Key facts
- Who runs it
- AIDS Malignancy Consortium
- Where
- Baltimore, La Jolla, Miami, New York, Salt Lake City, San Francisco, and Washington D.C., United StatesSee the 8 sites
- Trial code
- Registry title
- Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 10 May 2023
- Expected to end
- 31 Aug 2035
- Type of study
- Observational
- Treatments tested
- Biospecimen Collection
- Record updated
- 1 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a cancer who are living with HIV. People without HIV can also join if their cancer is linked to cancers that occur with AIDS. The trial collects blood and tissue samples for research.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- A diagnosed cancer, either newly diagnosed or recurrent. For people with HIV, a condition that raises the risk of cancer is also accepted.
- Biomarker or test result
- HIV infection must be shown by a medical record, antiretroviral therapy records, a HIV RNA test above 1000 copies/mL, or confirmed HIV antibody tests. People without HIV need a cancer linked to an AIDS-associated cancer.
Main reasons for not taking part
- Under 18 years of age
- HIV-negative with a cancer that has no established link to an AIDS-associated cancer
- Taking pre-exposure prophylaxis (PrEP) alone as the only HIV medicine
- Cannot give written informed consent, and has no legally authorized representative who can
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Participants must be at least 18 years of age
- Participant must be HIV- positive and have a diagnosed malignancy. If participants are HIV-negative, they must have a newly diagnosed or recurrent malignancy that has an established scientific connection (e.g., shared etiology) to an AIDS- associated malignancy such as:; classic Kaposi sarcoma; transplant-associated Kaposi sarcoma,; anal cancer,; multicentric Castleman's disease,; Epstein Barr Virus (EBV) -positive lymphoma; plasmablastic lymphoma; Hodgkin's lymphoma; For participants that are HIV-positive, HIV infection must be documented by means of any one of the following: :; Documentation of HIV diagnosis in the medical record by a licensed health care provider; Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider (Documentation may be a record of an ART prescription in the participant's medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name. Receipt of at least two agents is required; each component agent of a multi-class combination ART regimen will be counted toward the 2-agent requirement, excepting receipt of a pre-exposure prophylaxis (PrEP) regimen alone [e.g., Truvada], which is exclusionary); HIV ribonucleic acid (RNA) detection by a licensed HIV RNA assay demonstrating > 1000 RNA copies/mL; Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV Western blot confirmation or HIV rapid multispot antibody differentiation assay
- Participants with HIV infection, regardless of participation in an AMC clinical trial, must have a diagnosis of cancer, cancer or a condition that places them at a higher risk of cancer
- The investigator determines that the participant (or his/her legally authorized representative [LAR]) has the ability to provide informed consent and the participant or LAR provides written informed consent
Where in United States
- Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimore, United StatesContact: Laura ClarkTaking people
- UC San Diego Moores Cancer CenterLa Jolla, United StatesContact: Erin Reid, MDTaking people
- University of MiamiMiami, United StatesContact: Helen KattouraTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Ariela Noy, MDTaking people
- Mount Sinai HospitalNew York, United StatesContact: Keith Sigel, MDTaking people
- Huntsman Cancer Institute/University of UtahSalt Lake City, United StatesContact: Gayatri NachaegariTaking people
- University of California San FranciscoSan Francisco, United StatesContact: Ivan LeungTaking people
- George Washington UniversityWashington D.C., United StatesContact: Lakeisha McCormickTaking people
About the trial
What the trial wants to find out
This study collects blood and tissue samples for research of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)-related cancers. Collecting blood and tissue samples and studying biomarkers in the laboratory may help doctors to learn how are biologic or genetic factors related to HIV and cancers that occur commonly in people living with HIV.
The group in the trial
- Observational (biospecimen collection)
Patients undergo collection of fresh blood and/or tumor tissue samples
Treatment: Biospecimen Collection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Biospecimen Collection and Donation to the AIDS and Cancer Specimen Resource (ACSR): A Companion Protocol to AMC Trials
- Plain-language title
- Collecting Blood and Tissue Samples for HIV-Related Cancer ResearchGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 1 June 2026